Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma

Phase 2Not Yet RecruitingNCT02497898

The First People's Hospital of Changzhou1,000 enrolled

Overview

The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.

Autologous cytokine-induced killer (CIK) cells transfusion(\>2\*10\^9 cells count) within 2 weeks after regular chemotherapy every 3 months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

1,000

Conditions

Lymphoma, Non-Hodgkin

Interventions

Cytokine-induced killer cells (CIK)BIOLOGICAL

Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosed as non-Hodgkin lymphoma with negative effect of regular chemotherapy, and need further therapy Exclusion Criteria: * patients refuse the therapy or have no tolerance for the therapy

Outcomes

Primary Outcomes

Progression-Free-Survival (PFS)

Time frame: 1 month

Secondary Outcomes

Overall Survival (OS)

Time frame: 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.